Feinberg
Northwestern Medicine | Northwestern University | Faculty Profiles

News Center

  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
    • Podcast
  • Press Release
  • Media Coverage
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Menu
  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
    • Podcast
  • Press Release
  • Media Coverage
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Home » Skin Cancer Harbors Targetable Mutation
Disease Discoveries

Skin Cancer Harbors Targetable Mutation

By Will DossOct 7, 2021
Share
Facebook Twitter Email
Jaehyuk Choi, MD, PhD, the Jack W. Graffin Professor and an associate professor of Dermatology and of Biochemistry and Molecular Genetics, was senior author of the study published in Blood.

An especially deadly subtype of T-cell lymphoma is distinguished by unique mutations in a specific protein signaling pathway, according to a study published in the journal Blood.

Correcting the downstream effect of these mutations with a pharmacological inhibitor could prove a worthwhile treatment and further showcase the benefits of precision medicine, according to Jaehyuk Choi, MD, PhD, the Jack W. Graffin Professor and senior author of the study.

“All patients are different, but we tend to treat them all the same,” said Choi, who is also an associate professor of Dermatology and of Biochemistry and Molecular Genetics. “Our goal is precision medicine. This means we will develop simple molecular tests to identify the best way to treat individual patients.”

Cytotoxic cutaneous T-cell lymphoma (CTCL) is a rare but highly aggressive skin cancer. Previous studies have found mutations in the pathway known as JAK-STAT in other blood cancers, but that pathways’ association with CTCL was unknown.

In the current study, Choi and his collaborators performed genetic sequencing on archived biopsy samples of CD8+ aggressive CTCL, searching for mutations in the JAK-STAT. The investigators discovered several gene fusion events: whole chromosomes interacting with other chromosomes, all involving JAK2, a kinase in the pathway.

Tumor skin biopsy from two different patients. One patient who has a JAK2 gene fusion is positive for pSTAT3 staining, a marker of activated JAK-STAT signaling (left). Another patient who lacks the JAK2 gene fusion is negative for pSTAT3 (right). The patient with the JAK2 fusion is predicted to have good response to JAK2 inhibitors.

“These events are rare to begin with, so the fact that they all associate with JAK2 is astonishing,” said Katie Lee, a research fellow in the Choi laboratory, a medical student at the University of Illinois-Chicago and lead author of the study.

Further, these JAK2 mutations were nearly perfectly predictive of the aggressive CD8+ subtype, suggesting that the presence of those mutations could serve as a useful biomarker.

“Pathologists can see subtle differences between cancer subtypes under the microscope, and now we can link these differences directly to molecular aberration,” Choi said.

JAK2 mutations improve cancer proliferation but these downstream effects could be countered with a JAK2 inhibitor, and a clinical trial utilizing this strategy is already in progress.

“The molecular features of the mutation are as such that we have a very good reason to predict complete responses to this therapy,” Choi said. “We think this agent can offer a chance for a cure.”

Choi is a member of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University.

This study was supported by National Institute of Arthritis Musculoskeletal and Skin Diseases grant P30-AR066524; National Cancer Institute grants R35-CA231958 and P01-CA248384; Leukemia & Lymphoma Society grant SCOR 7026-21 and Doris Duke Charitable Fund grant 2020132.

Cancer Genetics Research
Share. Facebook Twitter Email

Related Posts

Epigenetic Biomarkers Predict CVD Risk

Jun 28, 2022

Hospitals Bound to Patient Safety Rules that Aren’t all Backed by Evidence

Jun 24, 2022

Identifying Protein Interactions that Promote Cancer Growth

Jun 24, 2022

Comments are closed.

Latest News

Epigenetic Biomarkers Predict CVD Risk

Jun 28, 2022

Student Spearheads Ukraine Aid Efforts

Jun 27, 2022

Hospitals Bound to Patient Safety Rules that Aren’t all Backed by Evidence

Jun 24, 2022

Identifying Protein Interactions that Promote Cancer Growth

Jun 24, 2022

Combination Treatment May Improve Quality of Life in Kidney Cancer

Jun 23, 2022
  • News Center Home
  • Categories
  • Press Release
  • Media Coverage
  • Editor’s Picks
  • News Archives
  • About Us
Flickr Photos
20220617_NM_0434
20220617_NM_0858
20220617_NM_0643
20220617_NM_0835
20220617_NM_0544
20220617_NM_0450
20220617_NM_0790
20220617_NM_0811
20220617_NM_0851
20220617_NM_0696
20220617_NM_0779
20220617_NM_0838

Northwestern University logo

Northwestern University Feinberg School of Medicine

RSS Facebook Twitter LinkedIn Flickr YouTube Instagram
Copyright © 2022 Northwestern University
  • Contact Northwestern University
  • Disclaimer
  • Campus Emergency Information
  • Policy Statements

Type above and press Enter to search. Press Esc to cancel.